* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Saying No: A biographical analysis of why women with a genetic
Survey
Document related concepts
Transcript
Saying No: A biographical analysis of why women with a genetic predisposition to developing breast/ovarian cancer reject risk reducing surgery. Dr Doreen Molloy, University of Glasgow Dr Joyce Hendricks, Edith Cowan University, Perth, WA Professor Anne Williams, Murdoch University, Perth, WA Content • Background to the study • Brief overview of Hereditary Breast/Ovarian Cancer (HBOC) syndrome and risk reducing surgery (RRS) • Aims of the study • Methodological approach • Why they said no to RRS • Conclusions and recommendations Background to the study • Personal drivers; • Professional drivers; – Working with women with breast and ovarian cancer. – Working with the “worried well” who had no diagnosis of disease. – Facing the possibility of having a familial disorder. – Increasing awareness of genetic risk as an issue in health care/society. – Identification of “cancer genes” and genetic testing. – Clinical guidelines for the management of HBOC. – Increasing number of women undergoing RRS for HBOC. – RRS moves from an “unthinkable step” (Thompson, 1994) to the principle primary intervention for cancer risk (Ingham et al., 2013). HBOC syndrome and RRS • RRM; – Total/subcutaneous/total skin sparing sporadic versus inherited mutation BRCA1 and BRCA2 mutations confer ~ lifetime risks of; • 40%-80% for breast cancer • 11%-40% for ovarian cancer • RRSO; – Both ovaries/fallopian tubes – Usually laparoscopic – Induction of menopause • RRS reduces breast cancer risk by up to 90% and ovarian cancer (Petrucelli et al., 2013) risk by up to 80% in high risk populations. (Ingham et al., 2013) BRCA1/2 mutations account for; • There is an association between • ~ 5-10% of all breast/ovarian RRS and improved survival in cancer high risk women, but further • ~ 25% of HBOC evidence is needed. (Domchek et al., (NCI, 2014) 2010) HBOC in the spotlight Reproduced with permission from copyright owners Angelina’s “heroic” medical choice I wanted to write this to tell other women that the decision to have a mastectomy was not easy. But it is one I am very happy that I made. My chances of developing breast cancer have dropped from 87% to under 5%. I can tell my children that they don’t need to fear they will lose me to breast cancer. (…) and they know that I love them and will do anything to be with them as long as I can. (…) I do not feel any less of a woman. I feel empowered that I made a strong choice that in no way diminishes my femininity. I want to encourage every woman, especially if you have a family history of breast or ovarian cancer, to seek out the information and medical experts who can help you through this aspect of your life, and to make your own informed choices. The message from Angelina’s story • RRS with reconstruction is an effective ‘cure’ for cancer risk and is therefore a ‘no-brainer’. • We have a “genetic responsibility” (Acero, 2012) to our children. • “A woman at genetic risk should feel empowered to remove both breasts as a way to prevent the disease” (Grady et al., 2013). BUT: some women have a different experience: those women’s experiences were the focus of this study. The aims of the study • To explore the experiences of high risk women who say no to RRS. • To create new knowledge regarding the refusal of RRS in high risk women within the framework of dominant Western discourses. • To make recommendations for the care, counselling and support of high risk women who refuse RRS. Methodological assumptions • Life/health experiences do not take place in a vacuum: societal, cultural and historical contexts shape experience. • HBOC is particularly challenging because it involves the removal of breasts and ovaries which are symbolic of femininity in Western culture. • High risk women make decisions about RRS within a framework of competing discourses. • In other words: the decision to say no to RRS must be interpreted within broader social, political and cultural frameworks in which life and experience take place. Methodological Framework Qualitative approach Denzin’s (1989) Interpretive Biography Dolby-Stahl’s (1985) Literary Folkloristic Methodology Literary Folkloristic Method Foucauldian literary theory Marxist literary theory Communal folklore/ cultural understandings Feminist literary theory Private folklore/ personal meaning Key concepts of each literary theory Foucauldian lens Concept of discourse Disciplinary power Power/knowledge and ‘the truth’ Marxist lens Medicine and ideology Ideology of genetic responsibility Commodification, genetics and the female body Feminist lens Femininity and the female role in Western society Social constructions of breast/ovarian cancer Patriarchy, power and resistance Study design • Eight-step literary folkloristic method. • Gathering of women’s stories and biographical timelines through semistructured interviews. • Interviews transcribed verbatim and salient themes identified. • Emerging themes interpreted through the three literary theories. • Multiple interpretations create meaning of why they said ‘no’. • paternal grandmother's death from breast cancer 1970s • secrecy surrounding diagnosis 1988 • mother's death from gastric cancer 1990 • father's death from prostate cancer • being strong for siblings 1992 • paternal aunt diagnosed /died from breast cancer • cancer more than bad luck/familial link • deadliness of cancer Feb 2007 Nov 2007 • sister diagnosed with breast cancer • realisation of seriousness of situation • sister tests positive for BRCA2 mutation • further evidence of familial link • inevitability of cancer March • Ann undergoes genetic testing 2008 Oct 2008 • Ann receives mutation-positive test result • no escape from cancer/death sentence • Ann refuses RRS March • bodily concerns 2009 • cancer is fate/destiny May 2011 • negative impact of testing • concern for children • constant threat of cancer Emerging themes Bodily concerns Doing the right thing How risk is experienced Conflict and contradiction Resistance Findings: why they said no • The genetic risk of cancer was not conflated with the disease of cancer hence risk was not ‘treatable’; • Differing perceptions of what ‘high risk’ meant; • Genetics was not considered to be the only ‘truth’ about why people develop cancer and genetic mutations were understood as only one of a number of equally important risks to health and life; • Breasts and ovaries were treasured as vital body parts which could not be given up or replaced on the basis of risk; • RRS was perceived as damaging the body and hence was a greater risk to self than genetic cancer risk; • RRS simply did not make sense given no disease was present and given the risks of surgery to body and self. Risk is not a disease • So it just seems so drastic. I don’t [said with emphasis] have cancer (…) but you are made to feel like you do. Who is having a heart transplant because they might get a heart attack in 10 years? It just doesn’t make sense when you are still healthy. It would be different if you already had it [cancer]. (R) • If I had cancer, then obviously I would not refuse surgery. But I still might not get it [cancer]. Having the gene doesn’t make it 100% you will get cancer (…). If I had cancer then I imagine I would want it all out, everything cut away. But they are cutting out something that’s not even there. (A) What does high risk mean? • The other thing was, they said with the gene fault the risk of cancer is really high. (…). 10 times higher than for other people, which made me think “well if it’s so high, it might happen anyway”, and they couldn’t say “no, it won’t happen”. So even with it [RRS] there’s no guarantee. Having this gene means there is a good chance of me getting cancer any way you look at it. (M) • Eventually the result came back as BRCA 2 positive and they told me my chance of getting breast cancer was about 50% and for ovary, about 15%, much higher than normal. I feel a bit silly admitting this but I thought the risk would be higher, like 100%. So yes it’s higher than if I didn’t have the gene, but it’s still not 100%. I thought if you had the gene, you got it [cancer] which was the first shock. (P) Risk and certainty • There’s no guarantees for any of us. I might get cancer or I might not. You might get it or you might not. I might have a stroke or get hit by a bus. (…) I think maybe because I smoke I don’t expect to live to a ripe old age anyway. (M) • I said “but mum, even if I get it done, I still might not be here for her [daughter], that’s life”. But she would just start crying again and, so, end of conversation. I think in the end I just decided to take my chances. If they could have given me a guarantee it might have been different. It just seemed so drastic, having all that done, when there’s nothing wrong with you (…) and not be able to say it definitely won’t happen. (S) • Then I find out even having them take them away [breasts and ovaries], you can still get it [cancer]. It was like opening a can of worms. (P) The paradox of risk – If I had surgery, every day I’d be thinking, “I’m not a whole woman, it’s not me”. Tom said it wouldn’t bother him but it would bother me [said with emphasis]. I wouldn’t be able to let him see me, look at me again, I don’t think.(R) – It’s funny because I’ve had a thing about my boobs since [having] kids. They were huge when I was pregnant and they never really went down again. I must have been a double G or something and now they are still probably an E cup. I’ve actually being going on for years before all this about a [breast] reduction. Then of course when faced with surgery and the thought of losing them, suddenly they seemed okay, great even. I became really attached to them. You start to be very conscious (…) of them being there, a part of you. Then knowing you won’t have them anymore, you really think about what a horrible loss it would be. (M) – I’ve seen Sheena’s [sister] [points to breast area] and I don’t like saying this, but it’s not pretty. I couldn’t cope with looking, you know, if I didn’t need to. It would be different if I actually had cancer. (…) I don’t like saying this because it’s saying something bad about other women who have had to have it done, but I would think I looked [makes ‘squeamish’ face], you know? (P) Conclusion Communal folklore Acceptance of RRS Alternative discourses Ideological practices Dominant discourses Saying no to RRS Personal ideologies Private folklore Transformed woman Resistance Recommendations • Use of holistic risk communication models which incorporate psychosocial elements. • Pro-active and tailored support for high risk women women who say no to RRS. • Encourage reflexive practice in HCPs who support high risk women. • Longitudinal research which examines women’s experiences and decisions over time. • More research into less damaging ways of dealing with cancer risk. Thank you for listening. References • • • • • • • • • • • Acero, L. (2012). Biocapital, biopolitics and biosocialities: Reframing health, livelihoods and environments with new genetics and biotechnology. In W. Harcourt, (Ed.), Women reclaiming sustainable livelihoods: spaces lost, spaces gained (pp. 221-237). Basingstoke, England: Palgrave Macmillan. Denzin, N. K. (1989). Interpretive biography. Beverley Hills, CA: SAGE Publications Inc. Macherey. Dolby-Stahl, S. K. (1985). A literary folkloristic methodology for the study of meaning in personal narrative. Journal of Folklore Research, 22(1), 45–69. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., ... & Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Journal of the American Medical Association, 304(9), 967-975 Grady, D., Parker-Pope, T. & Belluck, P. (2013, May 14). Jolie’s disclosure of preventive mastectomy highlights dilemma. New York Times. Retrieved from http://www.nytimes Hartmann, L.C. and Lindor, N.M., 2016. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. New England Journal of Medicine, 374(5), pp.454-468. Ingham, S. L., Sperrin, M., Baildam, A., Ross, G. L., Clayton, R., Lalloo, F., ... & Evans, D. G. R. (2013). Riskreducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Research and Treatment, 142(3), 611-618 Jolie, A. (2013, May 14). My medical choice. New York Times. Retrieved from http://www.nytimes National Cancer Institute. (2014). Genetics of breast and gynecologic cancers–for health professionals. Retrieved from http://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq Petrucelli N., Daly M., Feldman G.L. (2013). BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® Seattle (WA): University of Washington. Thompson, L. (1994, January 17). The breast cancer gene – a woman’s dilemma. TIME. Retrieved from http://content.time.com/time/magazine/article/0,9171,979978,00.html Summary of literary critiques • Marxist critique; – The creation of BRCA1/2 mutations as ‘cancer genes’ adds to their value as biocapital and effectively places a monetary value on cancer fear – Ideologies of risk impose a genetic responsibility on high risk women to make decisions for others. – An economic discourse underpins genetic medicine in which the ‘at risk’ body is conceived of as a potential source of economic gain for various stakeholders in the HBOC industry. – Breasts and ovaries are able to be understood as commodified as assets of varying worth which may be removed or replaced in the reconstruction marketplace. Foucauldian critique • The medical discourse transmits ‘the truth’ about HBOC and how it can be managed. • Genetics is a form of medical specialism which supports biopower – how the State disciplines and governs the body. • Genetic technology has expanded the medical gaze to include those with no disease. • Disciplinary power operates through genetic medicine, RRS and cancer surveillance. Feminist critique • Many discourses/competing ideologies mean women are conflicted in how to attend to cancer risk. • Genetic medicine disproportionately targets women because women bear offspring. • Reconstruction is necessary to appeal to the male gaze resulting in a need to “hide and fake” breast loss (O’Neill, 2013) and is therefore oppressive. • Saying no to RRS can be understood as resistance to the official medical pathway for managing risk, but this resistance was incomplete as they were unable to transform themselves in a positive way.